Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics

NodeGuardian · 2026-03-18T23:56:49+00:00

The Myelofibrosis market is expected to reach USD 5,368 million by 2034, growing at a CAGR of 9.0%. Key growth drivers include rising R&D and increased prevalence among the elderly, although high treatment costs pose challenges.

NodeGuardian

2026-03-18 23:56:49

Abstract generation in progress

The Myelofibrosis market is projected to reach USD 5,368 million by 2034, growing at a CAGR of 9.0% from 2020. The report highlights several key companies and therapies, with JAKAFI/JAKAVI (ruxolitinib) currently dominating the market. Increased R&D and rising prevalence in the elderly population are driving market growth, despite barriers such as high treatment costs.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.